Category VIEW ALL
Modified myeloid-derived suppressor cells for treating GvHD
Technology No. 20160072
A minipromoter for gene therapies
Technology No. 2023-188
Improved method for the synthesis of flurprimidol
Technology No. 20110095
Compounds that lead to degradation of cancer relevant proteins
Technology No. 2019-323
Anti-viral phosphoramidates for treating SARS-CoV and influenza
Technology No. 2022-040
Novel small molecule inhibitor to target metabolic plasticity
Technology No. 2022-152
Zika as an oncolytic virus to treat brain tumors
Technology No. 20170095
Didehydro-nucleoside antiviral agents
Technology No. 2023-032
Stable glutathione analog for the treatment of Alzheimer’s disease
Technology No. 20110150
Therapeutic target for treatment of ataxia
Technology No. 20160307
Use of extracellular vesicles to enhance colorectal cancer therapeutics
Technology No. 20170373
Hyperstable synthetic miniproteins as ligand scaffolds
Technology No. 2023-269
Progesterone receptor detection for breast cancer therapy
Technology No. 20170224
CDK2 inhibitors for cancer therapy and male contraception
Technology No. 2021-219
Nanorings for cell-mediated drug delivery
Technology No. 2022-267
Artificial gut/absorption simulator for evaluation of drug formulations dissolution
Technology No. 20170202
Efficient CRISPR-based gene editing for stem cells
Technology No. 2021-185
Single-cell Integration and DrUg Response PrediCtion (scIDUC)
Technology No. 2023-283
Pharmacological enhancement of CD8 T cell effector function using TEPP46
Technology No. 2022-294
First-in-class drug lead candidate (A229) for treating ocular diseases
Technology No. 2023-194
Bacterial histidine kinase inhibitors for treating Staphylococcus infections
Technology No. 2019-121
Small molecule inhibitors for treating alcoholic hepatitis
Technology No. 2022-250
InTERACCT Program: Occupational health and safety training
Technology No. 2023-191
Ovarian cancer prognostic test for predicting response to chemotherapy and bevacizumab
Technology No. 20180331
Bisubstrate inhibitors for treating SARS-CoV-2 infections
Technology No. 2022-100
Novel compounds for treatment of neurodegenerative disease and chronic pain
Technology No. 20160321
First-generation degraders for class I bromodomain-containing proteins
Technology No. 2022-132
NOD-2-active carboxamide compounds as vaccine adjuvants
Technology No. 2019-001
Lentivirus for keratinocyte immortalization and immortalized keratinocyte cell lines
Technology No. 2020-286
High-throughput screening assay for sickle cell disease drug discovery
Technology No. 2019-329
Mouse-derived FSHD muscle cell lines
Technology No. 2019-199
Small molecules with antiproliferative activity against pancreatic cancer cells
Technology No. 20160388
Steerable magneto-photonic particles for targeted delivery and collection of light
Technology No. 2023-107
Methods for Modifying Proteins and Peptides.
Technology No. 20180338
Pain therapy without the risk of respiratory depression, addiction or abuse
Technology No. 20160199
Cell-free selection of site-specific polypeptide binders via tethering
Technology No. 20170034
Compound with selective inhibition potential against P300 and CBT
Technology No. 2021-151
Live cell assay to quantify the activity of SARS-CoV-2 main protease, Mpro
Technology No. 2021-102
T cell receptors for engineered T cell therapy
Technology No. 2020-202
Nanominne-1: novel virus-like particle (nanoparticle) vaccines to prevent SARS-CoV-2 infections
Technology No. 2020-372
AGRP-derived melanocortin receptor ligands
Technology No. 20160310
Chimeric melanocortin receptor ligands
Technology No. 20160320
Selective melanocortin receptor ligands
Technology No. 20160305
Novel anti-cancer agents that target the epigenetic reader protein
Technology No. 2021-055
Assessing tumor behavior and response to therapy
Technology No. 20160224
Machine learning for early cancer detection
Technology No. 2019-197
Analgesic and anti-addictive compositions for treatment of chronic pain and opioid addiction
Technology No. 20170362
Fast and reliable neutralization antibodies assay for AAV gene therapy (2020-121)
Technology No. 2020-121
Adenovirus Vector Generating System (20110090)
Technology No. 20110090
Monoclonal Anti-FAP for cancer research and therapeutic development (2019-131)
Technology No. 2019-131
Antagomir to prevent cardiac arrhythmia (2019-069)
Technology No. 2019-069
A novel small molecule screening platform for tauopathies (2019-123)
Technology No. 2019-123
Opioid and Analgesic Chemical Compound Library (z09208)
Technology No. z09208
Carcinoma Immunotoxin Targeting Epidermal Growth Factor and Interleukin-4 Receptors
Technology No. z07098
Kappa Receptor Agonists and Delta Receptor Antagonists
Technology No. z01152
More Stable and Potent Cyclic ADP-Ribose Analogs
Technology No. 99184
Treating Neurodegenerative Diseases with Nicotine Receptor Ligands
Technology No. 99089
Minnesota LIVING WITH HEART FAILURE® Questionnaire (MLHFQ)
Technology No. 94019
Minnesota Solvation (MNSOL) Database
Technology No. 2020-340
Living with Pulmonary Hypertension Questionnaire (LPHQ)
Technology No. 2020-185
Selective bromodomain protein inhibitors that reduce cancer cell viability
Technology No. 2019-343
Reduce contamination from grains and powdered food
Technology No. 2019-244
A synergistic therapy for multi-drug resistant cancers
Technology No. 2019-141
3D tumor models for accurate testing of therapeutics
Technology No. 2019-018
A TLR-2 stimulatory molecule for use as a vaccine adjuvant
Technology No. 20180382
Antibody based treatment for Type 1 Diabetes
Technology No. 20180340
Immunostimulatory conjugates for targeted delivery as adjuvants
Technology No. 20180330
Drug Delivery Device for Oral Topical Medicine
Technology No. 20180269
Novel small molecules for chemotherapy sensitization
Technology No. 20180203
Assay to measure intrinsic efficiency of GPCR ligands
Technology No. 20180126
MHC Class II Molecules with Enhanced Co-receptor Affinity
Technology No. 20180109
A novel dual-action drug targeting cancer and respiratory syndromes
Technology No. 20180103
Tosedostat (CHR-2797) as a Potential Analgesic
Technology No. 20180059
Specific kinase biosensors to probe cancer metabolism
Technology No. 20170295
Probes for Biosynthesis of Bacterial Cell Wall
Technology No. 20170242-20170352
Unique compounds to treat obesity
Technology No. 20170238
Bacterial Histidine Kinase Inhibitor
Technology No. 20170232
Universal tyrosine kinase substrates
Technology No. 20170189
Solar UV-Induced Skin Cancer Inhibitor
Technology No. 20170106
Adaptive Immune Response Stimulated with TLR8 and Dual TLR7/TLR8 Agonists
Technology No. 20170196
Kinase assay to aid in development of therapeutics for acute myeloid leukemia
Technology No. 20160394
PDAC Treatment with High Antiproliferative Activity Against MiaPaca-2
Technology No. 20160388
Novel inhibitors of HINT1 to treat neuropathic pain and addiction
Technology No. 20160363
Biosynthetic Route to Serofendic Acid
Technology No. 20160338
Efficient release of affinity-captured cells
Technology No. 20160236
Nonsurgical Method for Restoring Tooth Enamel
Technology No. 20160189
Peptide Activation of T Cells for Cancer Immunotherapy
Technology No. 20160174
Improved Pertussis Vaccine
Technology No. 20160135
Algorithm for Discovering Genetic Interactions in Genome-Wide Association Studies (BridGE)
Technology No. 20160109
Live Attenuated Viral Vaccines
Technology No. 20160001
Midazolam Lysine Prodrug Rapid Delivery System (20150121, Dr. Ronald Siegel)
Technology No. 20150121
Potent HIV Integrase Inhibitor (20150106, Dr. Zhengqiang Wang)
Technology No. 20150106
High-efficiency Pyrrole Synthesis (20150075, Dr. Ian Tonks)
Technology No. 20150075
Circulating Tumor Cell Detection with New Reagents (20140299, Dr. Jayanth Panyam)
Technology No. 20140299
Mesoporous Silica-coated Iron Oxide Nanoparticle (20140249, Dr. Christy Haynes)
Technology No. 20140249
Protein Scaffold for Molecular Targeting Ligands (20140059, Dr. Benjamin Hackel)
Technology No. 20140059
Mesoporous silica nanoparticles with ultra high porosity
Technology No. 20140012
Prodrug with Enzyme Increases Absorption of Hydrophobic Drugs (20130297, Dr. Ronald Siegel)
Technology No. 20130297
Reagent for Dual Protein Labeling (20130255, Dr. Mark Distefano)
Technology No. 20130255
Analgesics for Inflammatory Pain (20130119, Dr. Philip Portoghese)
Technology No. 20130119
Aurora Kinase Inhibitors for Cancer Treatment (20120305, Dr. Zigang Dong)
Technology No. 20120305
Analogs of Cabergoline Lessen Side Effects (20120228, Dr. Peter Dosa)
Technology No. 20120228
Fractalkine Binding Aptamers for Drug Delivery (20120074, Dr. Efrosini Kokkoli)
Technology No. 20120074
Monocarboxylate Transporter (MCT) Inhibitors to Treat Hypoxic Tumors (20120012)
Technology No. 20120012
Lysosomal Storage Disease Enzyme Delivery System (20100076)
Technology No. 20100076